India’s COVAXIN shows 81 per cent efficacy
JNS: India’s first indigenous developed coronavirus vaccine, COVAXIN, has demonstrated an interim vaccine efficacy of 81 percent in Phase 3 clinical trials, said Bharat Biotech, a Hyderabad-based pharmaceutical company on Wednesday. …
India’s COVAXIN shows 81 per cent efficacy Read More